Selected Publications

  • Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy

    Patel, S. A., Dalela, D., Fan, A. C., Lloyd, M. R., Zhang, T. Y. Leukemia & lymphoma. 2021.

  • Reprogramming cancer into antigen presenting cells as a novel immunotherapy

    Linde, M. H., Gurev, S. F., Phan, P., Zhao, F., Gars, E. J., Stafford, M., Kohnke, T., Marshall, P. L., Fan, A. C., Dove, C. G., Linde, I. L., Miller, L. P., Majzner, R. G., Zhang, T., Majeti, R. AMER ASSOC CANCER RESEARCH. 2021.

  • IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia

    Zhang TY, Dutta R, Zhao F, Majeti R. Science Translational Medicine. 2020.

  • Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2

    Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., Stafford, M., Kaur, S., Nakauchi, Y., Yin, R., Azizi, A., Narla, A., Majeti, R. Journal of Clinical Investigation. 2020.

  • Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience

    Azizi A, Ediriwickrema A, Dutta, R, Patel SA, Shomali W, Medeiros B, Iberri D, Gotlib J, Mannis G, Greenberg P, Majeti R, Zhang TY. Leukemia & Lymphoma. May, 2020.

  • Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML

    Zhang, T. Y., Majeti, R. Cell stem cell. 2020.

Recent Publications

  • Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia

    Glaviano A, Weisberg E, Lam HY, Tan DJJ, Innes AJ, Ge Y, Lai CE, Stock W, Glytsou C, Smit L, Yoshida T, Zhang TY, Kennedy VE, Smith BD, Mercher T, de Botton S, Diana P, Konopleva M, Mauro MJ, Griffin JD, DiNardo CD, Kumar AP. Nat Rev Clin Oncol. Sep, 2025.

  • The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data

    Schwede M, Rodriguez G, Kennedy VE, Henry S, Wood D, Mannis GN, Majeti R, Chen JH, Bendavid E, Zhang TY. Haematologica. Jul, 2025.

  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

    Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B, Maltos AM, Silva O, Stehr H, Hovanky V, Duran G, Zhang T, Liedtke M, Arai S, Iberri D, Miklos D, Khodadoust MS, Sidana S, Kurtz DM. Nat Commun. Feb, 2025.

  • MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis

    Khanna V, Eslami G, Reyes R, Diep R, Fernandez-Pol S, Stehr H, Suarez CJ, Pinto H, Ford JM, Zhang TY, Chen CT. NPJ Precis Oncol. Feb, 2025.

  • Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis

    Xie Y, Kazakova V, Weeks LD, Gerber JM, Tai J, Zhang TY, Lowsky R, Wu X, Yang C, Patel SA. Bone Marrow Transplant. Aug, 2024.

  • Natural history of clonal haematopoiesis seen in real-world haematology settings

    Patel, S. A., Gerber, W. K., Zheng, R., Khanna, S., Hutchinson, L., Abel, G. A., Cerny, J., DaSilva, B. A., Zhang, T. Y., Ramanathan, M., Khedr, S., Selove, W., Woda, B., Miron, P. M., Higgins, A. W., & Gerber, J. M. British journal of haematology. March, 2024

  • p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes

    Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., Zhang, T. Y., Gratzinger, D., Oak, J., Silva, O., Kurzer, J., Tan, B., Menke, J. R., & Fernandez-Pol, S. American journal of clinical pathology. April, 2024.